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Abstract TNF-blocking agents, non-biological disease-
modifying anti-rheumatic drugs (nbDMARDs) and non-
steroidal anti-inflammatory drugs (NSAIDs) are commonly
prescribed treatments in psoriatic arthritis. A large proportion
of patients do not respond to these medications, although un-
fortunately clinically useful biomarkers that predict future re-
sponse are currently lacking. Several candidate gene polymor-
phisms have been associated with responses to biologic ther-
apies and nbDMARDs; however, replication and validation of
these variants in large prospective psoriatic arthritis cohorts
are required before translating these to clinical practice. In this
review, we discuss the advances made in pharmacogenetics of
treatment response in psoriatic arthritis to date, with focus on
biologic therapies approved for use, nbDMARDs and NSAI
Ds, as well as outline emerging methodologies to obtain data
that will help inform a future precision medicine approach in
this condition.
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Introduction
Psoriatic arthritis (PsA) is an inflammatory arthritis, with an
estimated overall prevalence of 0.3–1 % [1]. PsA represents a
heterogeneous disease with a spectrum of disease severity and
expression. This may range from mild symptoms requiring
minimal intervention to a rapidly destructive and disabling
course leading to loss of function. To preserve long-term qual-
ity of life, treatment strategies with the aim of abrogation of
inflammation and eventual remission/low disease activity are
recommended, with evidence supporting a treat-to-target ap-
proach similar to rheumatoid arthritis [2•, 3, 4•]. Although the
last decade has seen a number of paradigm changes in the
therapeutic options for PsA, response to treatment is highly
variable. Current therapeutic strategies include non-steroidal
anti-inflammatory drugs (NSAIDs), non-biologic disease-
modifying anti-rheumatic drugs (nbDMARDs) and biologic
agents such as tumour necrosis factor inhibitors (TNFis).
Although TNFi agents are highly effective treatments, they
cost £10,000 per patient per year in the UK and up to 30–
40 % of patients do not respond [5, 6]. The wide inter-
individual variability in drug efficacy and toxicity to all agents
has meant that clinicians are reliant on a ‘trial and error’ ap-
proach and sequential intervention as per their national con-
sensus recommendations. However, by targeting treatments to
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the strata of patients most likely to respond (stratified or pre-
cision medicine), they could be utilised more cost-effectively,
as well as increasing the success rates of first-line treatments
and fast-tracking PsA patients destined to require biologic
therapies to prevent irreversible joint damage.
Biomarkers in PsA to predict disease prognosis and treat-
ment response are currently lacking in clinical practice. A
biomarker is a biological characteristic that is measured and
evaluated objectively as an indicator of normal biological pro-
cesses, pathogenic processes or pharmacological response to
therapeutic intervention [7]. The availability of sensitive, spe-
cific, reproducible and predictive biomarkers in PsA would
have immediate implications for a precision medicine ap-
proach as well as better tailoring of emerging new treatments.
Most recently, a panel of synovial proteins was found to pre-
dict response in a small number of adalimumab-treated PsA
patients and in combination acting as potential biomarkers [8].
The transition from conventional approaches to better
personalisation utilising biomarkers, in selecting the most ef-
ficacious treatment with the least adverse events for a given
individual, will likely require consolidated expertise from a
number of sectors. One such approach is pharmacogenetics,
which can be defined as the study of the variability in drug
response because of heredity [9]. Specific advantages of phar-
macogenetics are that genetic variants are inexpensive to as-
say, are stable over time and can provide clues to causality and
pathogenesis [10•].Most importantly, they occur prior to com-
mencing treatment rather than being produced as a conse-
quence [10•], with therefore promising potential for use as
predictive biomarkers. Herein, we review the progress that
has been made to date in the identification of genetic bio-
markers of pharmacological treatment response in PsA, focus-
sing on biologics approved for use, nbDMARDs and NSAI
Ds, with reference to other chronic inflammatory disease phar-
macogenetic studies where appropriate.
Genetic Predictors of Response to Biologic Therapy
Tumour Necrosis Factor Inhibitors
Biologic agents are being used increasingly to treat moderate
to severe PsA patients in whom conventional treatments have
failed. There are two broad classes of TNFis approved for use
in PsA: monoclonal antibodies to TNF (infliximab,
adalimumab, golimumab, certolizumab pegol) and the TNF
fusion protein receptor inhibitor (etanercept). A limited num-
ber of pharmacogenetic studies to predict TNFi treatment re-
sponse have been conducted to date specifically in PsA. All
such studies in PsA have used a candidate gene approach,
where genes are selected for investigation based on knowl-
edge of the biological pathways they lie on and the therapeutic
agent to which response is being assessed.
Polymorphisms within the TNF promoter region have been
identified to influence clinical efficacy of etanercept in a study
that combined patients with rheumatoid arthritis (RA), anky-
losing spondylitis and PsA [11] (Table 1). In this study, the
−308 G/G (rs1800629) genotype in the promoter of the TNF
gene conferred a better response to treatment than A/A or A/G
genotypes. Only 10 patients with PsAwere included; howev-
er, it is promising to note a meta-analysis of similar studies of
this polymorphism, which included 692 RA patients treated
with infliximab, adalimumab or etanercept, showed that the
−308(A) variant predicts poor response to TNFis. In the latter
analysis, irrespective of the prescribed TNFi, the frequency of
the TNF –308A variant was 22 % in responders, compared
with 37 % in non-responders [OR=0.4, 95 % confidence in-
terval (CI) 0.4–0.7; P=0.000245]. In another small PsA study
(n=58), which assessed single-nucleotide polymorphisms
(SNPs) at positions −238 (rs361525), −308 and −489
(rs80267959) of the TNF-α gene in response to TNFis, the
−489A allele showed a trend of association with PsA response
to etanercept (not significant). However, in that Italian
Caucasian population, the association with the −308 G/G ge-
notype was not replicated [12].
The TNF receptor 1A (TNFR1A) variant rs767455/G36A
in PsA patients has been associated with a better European
League Against Rheumatism (EULAR) response at 3 months
to infliximab both with the AA genotype (AA 85 % vs. AG/
GG 58.9 %; P=0.04) and with the A allele (A 76.7 % vs. G
58.3 %; P=0.03) [13]. Interestingly, this was in the opposite
direction to RA patients in the same study, whilst a Crohn’s
disease cohort also found biological response to infliximab
was lower in patients carrying TNFR1 36G mutation in the
TNFR1 gene [14]. In the same study [13], TNF-related apo-
ptosis-inducing ligand receptor 1 (TRAIL-R1) rs20575 CC
genotype was also associated with a 6-month EULAR re-
sponse to infliximab in PsA (Table 1). In psoriasis, polymor-
phisms in TNFAIP3 are associated with response to TNFis,
with the SNPs (rs2230926 and rs610604) acting as markers
of beneficial response to three TNFis tested [15]. TNFAIP3,
which has also been identified as a susceptibility locus for PsA
[16], is a gene encoding the A20 protein, a TNF-α-inducible
zinc finger protein thought to limit NF-κB-mediated immune
responses. Therefore, there is some evidence that polymor-
phisms affecting TNF may affect treatment response to
TNFis in PsA patients; however, this may vary according to
disease and drug subtype, and larger validation studies are
required to confirm these associations.
The presence of the high-affinity FCGR2A-131H allele in
either homo/heterozygous combinations (HH and HR) in PsA
patients receiving etanercept showed a strong trend to a higher
rate of EULAR response compared with those without a re-
sponse (93 vs. 67 %; P=0.034) [17]. FCGR2A, located on
chromosome 1, encodes one member of a family of immuno-
globulin Fc receptor genes found on the surface of many
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immune response cells. The protein encoded by this gene is a
cell surface receptor and is involved in the process of phago-
cytosis and clearing of immune complexes. A smaller PsA
study, which evaluated the specific distribution of the
FCGR3A V158F polymorphism in relation to infliximab re-
sponse at 3, 6, and 12 months, found that more patients with a
high-affinity genotype (FV+VV) achieved a EULAR re-
sponse at 3 months (20 % FF vs. 83.3 % FV-VV; P=0.036,
P=0.067) [18]. This association however was not significant,
limited by the small numbers of patients in the study and
hence study power.
The prevalence of axial involvement amongst patients with
PsA has been reported to be between 25 and 70 %, depending
on the criteria used for its definition [19], and PsA is also
known to share susceptibility loci with ankylosing spondylitis
(AS) [20, 21•]. Few studies have analysed the role of genetic
markers in the response to TNFi therapy in AS patients, but
the majority have shown an association of favourable re-
sponse with HLA-B27 status [22, 23]. Outside the MHC,
one study suggested variants within macrophage migration
inhibitory factor (MIF) gene (rs755622), interleukin 18 recep-
tor accessory protein (IL18RAP) gene (rs917997), IL10
(rs1800896), TNF receptor superfamily member 1B
[(TNFRSFB1); rs4355801] and ADP-ribosylation factor
GTPase-activating protein 2 (ARFGAP2) gene (rs3740691),
were associated with non-response in 121 AS patients [24].
These results are yet to be replicated independently.
In RA, only two associations with TNFi treatment response
have approached genome-wide significance (P<5×10−8) and/
or have been replicated in independent cohorts. These include
a polymorphism in the CD84 gene (rs6427528; G>A) which
encodes SLAM family member 5 and has been associated
with reduced response to etanercept [25]; the PDE3A–
SLCO1C1 locus (rs3794271; C>T) was associated with re-
duced efficacy to the TNFis etanercept, infliximab and
adalimumab [26]. Larger homogenous cohorts are required
to more accurately assess and replicate these variants to eval-
uate if they can predict response to TNFis specifically in PsA
patients, to inform future clinical decisions regarding treat-
ment selection.
Genetic Predictors of Response to Other Treatment
Non-biologic Disease-Modifying Anti-rheumatic Drugs
Methotrexate
Methotrexate, a folate antagonist, is the most commonly used
systemic nbDMARD in PsA. Although the mechanism of
action in PsA is not fully understood, methotrexate requires
intracellular uptake and inhibits enzymes of the folate, purine
and pyrimidine pathways. Given the considerable inter-
individual variability in response (and approximately 30 %
of treated individuals developing hepatotoxicity [27] or gas-
trointestinal adverse events), reliable biomarkers to predict
response at the outset would be extremely beneficial to help
optimise current treatment regimens.
Pharmacogenetic studies assessing methotrexate response
specifically in PsA are sparse. The gene polymorphisms
which influence metabolism of methotrexate may be classi-
fied into those that influence methotrexate transport across the
cell membrane and those that influence enzymes in the cellu-
lar pathway of methotrexate [28]. One study, which assessed
119 PsA patients, evaluated associations between effective-
ness, toxicity, and drug survival and polymorphisms of genes
coding for the folate pathway enzymes methylenetetrahydro-
folate reductase (MTHFR), dihydrofolate reductase (DHFR)
and reduced folate carrier (RFC) [29]. A polymorphism in the
DHFR gene was associated with better methotrexate response
(Table 1). The DHFR enzyme converts dihydrofolate to tetra-
hydrofolate, required for DNA synthesis and cell growth.
Although DHFR is inhibited by methotrexate, it is unclear if
this inhibition is crucial to its anti-inflammatory effects.
Interestingly, PsA patients homozygous for the minor allele
of MTHFR 677C/T (677TT (rs1801133)) had more liver tox-
icity [29]. Studies in RA investigating polymorphisms in the
MTHFR gene, as predictors of response to methotrexate, have
reported conflicting results [30, 31]. A previous meta-analysis
evaluating key polymorphisms of C677T (rs180113) and
A1298C (rs1801131) within MTHFR established they were
not reliable predictors of treatment response, although it was
acknowledged that there was substantial heterogeneity within
the studies [32].
Sulphasalazine
Sulphasalazine can be effective for joint pain and skin disease
in PsA [33, 34]. Following ingestion, a small amount is
absorbed systemically, whilst the majority is reduced by intes-
tinal bacteria to 5-aminosalicylic acid and sulphapyridine. In
the liver, an acetate group is added to the sulphapyridine by
the phase II enzyme N-acetyltransferase 2 (NAT2) to form N-
acetyl sulphapyridine, which subsequently undergoes renal
excretion [35]. NAT2 is encoded by an 870-bp gene (NAT2),
and 40–70 % of individuals are either homozygous or com-
pound heterozygous for NAT2 polymorphisms [36], which
influences whether individuals are rapid, intermediate or slow
acetylators. Most NAT2 variant alleles include one or more of
the following seven most frequent SNPs: rs1801279 (191G>
A), rs1041983 (282C>T), rs1801280 (341 T>C), rs1799929
(481C>T), rs1799930 (590G>A), rs1208 (803A>G) and
rs1799931 (857G>A) [37]. With rapid acetylators having
lower plasma concentrations, they may be less prone to ad-
verse events, however may require higher doses to maintain
efficacy. The main route of elimination of sulphasalazine is
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faecally, which is mediated by ATP-binding cassette protein
G2 (ABCG2), a transmembrane protein that transports
sulphasalazine into the intestinal lumen [38].
A recent study that evaluated 229 patients with early RA on
sulphasalazine (+/− combination therapy) revealed that NAT2
acetylator status (rs1041983) was associated with higher inci-
dence of adverse events but not associated with efficacy [38].
Interestingly, the ABCG2 genotype (rs2231142) was associat-
ed with remission in RA (odds ratio 3.34 (95%CI 1.18–9.50),
P=0.024), even after adjustment for confounders and in the
sensitivity analysis which assessed Caucasian patients only. A
small study also suggested genetic polymorphisms of NAT2
leading to differences in acetylator status may account for
variation in the response to sulphasalazine in patients with
discoid lupus [39]. Furthermore, studies in RA [40, 41] and
most recently in ankylosing spondylitis [42] suggest NAT2
variants, which lead to slow acetylator status, may contribute
to adverse events in sulphasalazine-treated patients. These re-
sults however do require replication in independent cohorts,
and further work needs to be performed to extrapolate these
results to PsA patients.
Leflunomide
Leflunomide inhibits de novo pyrimidine synthesis, leading to
inhibition of T cell proliferation and activation, potentially
targeting the underlying pathophysiologic events in PsA, pso-
riasis and RA. Its metabolite teriflunomide causes non-
competitive and reversible inhibition of dihydroorotate dehy-
drogenase (DHODH), the key enzyme required for pyrimidine
synthesis [43]. In RA, a number of studies have evaluated
polymorphisms within the DHODH gene: Firstly, Pawlik
et al. studied 147 RA patients on leflunomide monotherapy
and found that remission was more frequent in patients who
carried a common missense polymorphism in the coding re-
gion (rs3213422 19 C>A). A small study assessing disease
activity in 56 RA patients at 3 months suggested carriage of a
six-marker DHODH haplotype was associated with reduced
treatment response in the short term [44]. Finally, a retrospec-
tive RA study in 105 patients suggested DHODH A40C was
associated with a 6.8-fold increased risk of overall toxicity
related to the drug; however, efficacy was not assessed [45].
In vitro studies have suggested oestrogen interferes with
suppression of cytokine production by leflunomide [46, 47].
Oestrogen acts through the receptors ESR1 and ESR2, and the
genes encoding for them are responsible for transducing ex-
tracellular signals into transcriptional responses.
Polymorphisms within the genes encoding the oestrogen re-
ceptors (ESR1 and ESR2) in women have been therefore in-
vestigated. In a study carried out on 115 women on
leflunomide, a better response to treatment in patients was
observed with ESR1 rs9340799 AA and rs2234693 TT geno-
types after 12months of therapy (a worse response with the G-
C haplotype) [48]. Teriflunomide also inhibits tyrosine ki-
nases, including p56LCK and p59FYN, both of which are
candidate substrates for the PTPN22–CSK complex. More
recently, the PTPN22 genotype (rs2476601), known to be a
strong susceptibility locus for RA, was evaluated as a predic-
tor of response/toxicity to leflunomide therapy in a small
group of RA patients in which no association was found [49].
A previous study on human liver microsomes suggested
that cytochromes (CYP450) are involved in leflunomide acti-
vation, and the major enzymes responsible for leflunomide
metabolism are CYP1A2, CYP2C19 and CYP3A4 [50]. In a
prospective RA study, which compared 62 patients who tol-
erated the drug vs. 43 who discontinued due to adverse events
(6 due to inefficacy), the CYP1A2*1F (CC>A) had a 9.7-fold
higher risk for overall leflunomide-induced toxicity [51]. In a
retrospective cohort study of 78 patients, the CYP2C19 phe-
notype was associated with cessation due to toxicity [52],
most of whomwere also on a concomitant DMARD, although
these results conflict with the findings of previous studies [45,
53]. To date, there have been no studies assessing the pharma-
cogenetics of leflunomide in PsA. Current evidence suggests a
possible diagnostic value of genotyping patients with RA as
biomarkers, although future studies need much larger sample
sizes, longer follow-up and replication of the above variants
and across disease areas such as PsA.
Other Non-biologic Disease-Modifying Anti-rheumatic Drugs
Other nbDMARDs infrequently used in the treatment of PsA
include hydroxychloroquine and ciclosporin. There are no
pharmacogenetic studies evaluating hydroxychloroquine as
monotherapy in inflammatory arthritis. Ciclosporin polymor-
phisms have been evaluated previously in paediatric trans-
plantation candidates only [54] and most recently to assess
3-month treatment response of psoriasis patients [55]. In the
latter study, the ABCB1 C3435T (rs1045642) polymorphism
was found to be associated with a reduced response to
ciclosporin, in both SNP and haplotype analyses. ABCB1 is
known to affect P-glycoprotein levels, lower levels of which
may impair drug transport and thus reduce efficiency of
therapy.
Non-steroidal Anti-inflammatory Drugs
NSAIDs are frequently used as adjunct treatments in PsA for
pain relief and improving inflammatory symptoms. A sub-
group of PsA of patients will experience worsening of their
psoriasis when on this class of drugs. The metabolism of
NSAIDs is highly regulated by the cytochrome P450 en-
zymes, which comprise a category of proteins whose biosyn-
thesis is controlled by a large superfamily of genes. NSAIDs
are primarily metabolised by the polymorphic CYP2D9 gene,
which has over 70 variable alleles and may vary from each
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other in only one nucleotide [56]. CYP2D9 allele frequency is
variable across ethnicities with the functional group of alleles
predominant in approximately 70 % of European Caucasians,
whilst Asians and Pacific Islanders have a high frequency
(∼40 %) of a reduced function allele, CYP2D6*10, leading
to slower drug metabolism [57]. Individuals with several var-
iant alleles (such as CYP2C9*2 and CYP2C9*3) have dem-
onstrated decreased metabolic clearance compared with indi-
viduals with the wild-type enzyme (CYP2C9*1) [58]; howev-
er, prediction of NSAID drug dosing regimens based on
genotyping alone remains challenging. To date, there are no
specific studies of CYP2C9 genotypes as predictors of PsA
response or to identify in which individuals psoriasis may
worsen.
Challenges and Future Directions
With emerging novel biologic targets and expansion of the
PsA therapeutic armamentarium, the identification of reliable
and predictive genetic markers of therapeutic response to op-
timise the cost/benefit ratio of these expensive yet effective
drugs has become increasingly important. Unfortunately,
large-scale studies performed in ethnically homogenous pop-
ulations and in PsA patients followed up for an adequate pe-
riod of time are lacking; therefore, pharmacogenetic studies
have been underpowered to translate these findings to clinical
practice. Several issues confound interpretation of the outlined
studies. PsA is a complex polygenic disease, with significant
phenotypic heterogeneity. Outcomemeasures used tomeasure
treatment response can be highly inconsistent between studies,
making results in the same disease subset difficult to extrapo-
late. An effort to standardise such measures is currently un-
derway by the Outcome Measures in Rheumatoid Arthritis
Clinical Trials (OMERACT) PsA special interest group [59],
which will be helpful to inform future core minimal set of
outcomes not only in trials but also in longitudinal studies.
In some cases, genetic polymorphisms identified as potential
predictors of treatment response may also be markers of more
severe disease, leading to an increased response to TNFi
agents (normally prescribed to the most severely affected
PsA individuals).
The multifactorial nature of treatment response make small
genetic effects difficult to discover even from genome-wide
association studies, which have not yet been conducted for
this purpose in PsA. The search for genetic variations
influencing therapeutic response may also be affected by fac-
tors not related primarily to a drug’s mechanism of action. An
important mechanism for treatment failure of biologics is im-
munogenicity or the formation of anti-drug antibodies, partic-
ularly in response to monoclonal antibodies. In the case of
adalimumab, they may be formed in around 22 % of PsA
patients and lead to treatment failure [60]; their occurrence is
further influenced by use/dose of concomitant nbDMARDs
such as methotrexate amongst other factors [61]. Etanercept
does not appear to develop detectable anti-drug antibodies that
neutralise the effect of the drug; therefore, differential predic-
tive genetic variants in patients treated with this drug alone
may be plausible. Furthermore, immunogenicity in PsA may
itself vary between carriers of undiscovered genetic factors,
and these influences could contribute to genetically based loss
of response. Additional important issues in determining treat-
ment response include adherence to rheumatic drugs, which
may be as low as 30 % [62, 63], and a current lack of
standardisedmethods ofmeasurement to facilitate comparison
between studies.
In the future, a precision medicine approach in PsA pre-
scribing is likely to require integration of serological markers,
pharmacological biomarkers as well as emerging technologies
and methodologies currently being used in other disease areas.
Epigenetic changes are inheritable modifications to DNA not
caused by variation in its primary nucleotide sequence and
may lead to DNA methylation changes and histone modifica-
tion affecting treatment response as seen in RA [10•]. A com-
plementary approach in the identification of predictive
markers is whole-genome expression profiling or transcripto-
mics which provides information on which genes are actively
being expressed at a given time. In biologic-treated RA pa-
tients, the interferon signature has been correlatedwith clinical
response (reviewed previously by Smith et al. [64]). Although
epigenetics and transcriptomics in determining PsA treatment
response remain unexplored, future work investigating these
aspects offers exciting potential for correlating genetics and
gene expression data with treatment outcomes.
Expensive drugs such as biologics with high rates of
primary/secondary non-response and medications with a nar-
row therapeutic index leading to severe adverse effects (e.g.
certain nbDMARDs) are to be the ideal candidates for explo-
ration of pharmacogenetic biomarkers. Psoriasis and PsA sus-
ceptibility loci [20, 21•] could be targeted in future candidate
gene studies, given some evidence that RA susceptibility
genes associate with response [65]. In the future, the develop-
ment of a ‘pharmacogenetic signature’ [20] which incorpo-
rates multiple genetic variants that predict the efficacy and
toxicity of a given drug, combined with emerging biomarkers
as above, could contribute to a personalised medicine ap-
proach in PsA and tailoring of these expensive drugs to an
individual patient.
Conclusion
In summary, although pharmacogenetics in PsA is still in its
infancy, it holds promise towards introducing a precisionmed-
icine approach in clinical practice. Given the advances in ge-
netic technology and new targeted anti-cytokine therapies
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emerging, there will be real potential for translating genetic
biomarkers from bench to bedside. However, future studies
will need to be adequately powered, and results replicated
and validated in independent cohorts, with adequate health
economic evaluation before they can be adopted widely in
clinical practice. The need to treat inflammatory arthritides
such as PsA with the right treatment first time to prevent
long-term joint damage and disability, the variable response
and toxicity to treatments, the current cost of effective treat-
ments such as TNFis and the emergence of new biologics for
its treatment make PsA a worthwhile disease model to assess
the utility of a precision medicine approach. In the future, it
will be imperative to encompass known demographic, sero-
logical, immunological and genomic biomarkers and correlate
with robust outcome measures when assessing the additional
benefits of prospective genetic testing.
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